---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-027958"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2023-06-14T23:59:59+00:00"
generated_at: "2026-06-14T01:27:39.766221+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Cullinan Oncology transitions CSO Patrick Baeuerle to advisor; stockholders elect directors

## Summary
- Dr. Baeuerle transitions from Chief Scientific Officer to Co-Founder & Chief Scientific Advisor, effective June 8, 2023.
- Consulting agreement: $40,556 monthly, max $480,000/year, with bonus opportunity (40% in 2023, 25% thereafter).
- Stockholders elected Nadim Ahmed (28,651,746 votes for) and Stephen Webster (21,598,415 for) as Class III directors.
- Ratification of KPMG LLP as independent auditor for FY2023 approved with 34,563,271 votes for.
- Term of consulting agreement runs through Dec 31, 2024, with annual auto-renewal; either party may terminate on 180 days notice.

## SEC filing metadata
- accession: 0000950170-23-027958
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2023-06-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000095017023027958/0000950170-23-027958-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000095017023027958/cgem-20230608.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-027958
- JSON: https://secwatch.observer/filing/0000950170-23-027958.json
- Plain text: https://secwatch.observer/filing/0000950170-23-027958.txt

## Key facts
- Executive change
  Patrick Baeuerle changed role as Co-Founder, Chief Scientific Advisor at Cullinan Therapeutics, Inc..
  - Action: transitioned
  - Role: Co-Founder, Chief Scientific Advisor
  source text: Upon mutual agreement between Patrick Baeuerle and Cullinan Oncology, Inc. (the “Company”), Dr. Baeuerle will transition from Chief Scientific Officer of the Company to Co-Founder, Chief Scientific Advisor of the Company effective June 8, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789972/000095017023027958/0000950170-23-027958-index.htm
- Shareholder Votes
  Cullinan Therapeutics, Inc. shareholders approved Election of two Class III directors to serve for three-year terms at the 2023-06-08 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-08
  source text: Proposal One — Election of Directors The Company’s stockholders elected two Class III directors to the Company’s Board of Directors for three-year terms or until his successor has been duly elected and qualified, or until his earlier death, resignation or removal, by the following votes: Nominee Votes For Votes Withheld Broker Non-Votes Nadim Ahmed 28,651,746 346,553 5,838,068 Stephen Webster 21,598,415 7,399,884 5,838,068
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789972/000095017023027958/0000950170-23-027958-index.htm
- Shareholder Votes
  Cullinan Therapeutics, Inc. shareholders approved Ratification of appointment of KPMG LLP as independent registered accounting firm for fiscal year ending December 31, 2023 at the 2023-06-08 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-08
  source text: Proposal Two — Ratification of Appointment of Independent Registered Accounting Firm The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2023 by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 34,563,271 272,925 171 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789972/000095017023027958/0000950170-23-027958-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.